Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Phase 1 Clinical Study

Devinsky, Orrin; Kraft, Kelly S.; Rusch, Lorraine M.; Fein, Melanie; Leone-Bay, Andrea

doi:10.1016/j.xphs.2021.08.012

Cited by 29 publications

(20 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Devinsky et al 71 compared the pharmacokinetics of 50 mg oral CBD to 2.1 mg CBD delivered using dry powder inhaler technology. As expected, pulmonary delivery accelerated absorption and increased bioavailability of CBD compared to oral administration.…”

Section: Resultsmentioning

confidence: 99%

The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence

Arnold

McCartney

Suraev

et al. 2022

Clinical Translational Sci

View full text Add to dashboard Cite

Global interest in the non‐intoxicating cannabis constituent, cannabidiol (CBD), is increasing with claims of therapeutic effects across a diversity of health conditions. At present, there is sufficient clinical trial evidence to support the use of high oral doses of CBD (e.g., 10–50 mg/kg) in treating intractable childhood epilepsies. However, a question remains as to whether “low‐dose” CBD products confer any therapeutic benefits. This is an important question to answer, as low‐dose CBD products are widely available in many countries, often as nutraceutical formulations. The present review therefore evaluated the efficacy and safety of low oral doses of CBD. The review includes interventional studies that measured the clinical efficacy in any health condition and/or safety and tolerability of oral CBD dosed at less than or equal to 400 mg per day in adult populations (i.e., ≥18 years of age). Studies were excluded if the product administered had a Δ9‐tetrahydrocannabinol content greater than 2.0%. Therapeutic benefits of CBD became more clearly evident at doses greater than or equal to 300 mg. Increased dosing from 60 to 400 mg/day did not appear to be associated with an increased frequency of adverse effects. At doses of 300–400 mg, there is evidence of efficacy with respect to reduced anxiety, as well as anti‐addiction effects in drug‐dependent individuals. More marginal and less consistent therapeutic effects on insomnia, neurological disorders, and chronic pain were also apparent. Larger more robust clinical trials are needed to confirm the therapeutic potential of lower (i.e., <300 mg/day) oral doses of CBD.

show abstract

Section: Resultsmentioning

confidence: 99%

The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence

Arnold

McCartney

Suraev

et al. 2022

Clinical Translational Sci

View full text Add to dashboard Cite

show abstract

“…Thus, it was quite difficult to justify a suitable daily dose [ 24 , [27] , [28] , [29] ]. In a recent phase 1 clinical study of CBD dry powder inhaler, the authors reported a C max of 18.78 ng/mL of CBD [ 30 ], and in general the lung drug concentration should be about 100-fold higher than the concentration in the plasma [ 31 ]. Also, it is worth noting that the extravascular lung fluid according to various reports is about 2–10 mL [ 32 , 33 ].…”

Section: Resultsmentioning

confidence: 99%

Oral inhalation of cannabidiol delivered from a metered dose inhaler to alleviate cytokine production induced by SARS-CoV-2 and pollutants

Srichana

Chunhachaichana

Suedee

et al. 2022

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

“…Various oral CBD formulations are available, such as oil drops and oil in capsules [12]. However, oral CBD has demonstrated the lowest bioavailability of 6-19% compared to other delivery routes due to irregular absorption and extensive hepatic metabolism [15,16,133]. The high lipophilicity of CBD also contributes to poor and slow absorption as precipitation can occur in the gastrointestinal tract [14].…”

Section: Oral Administrationmentioning

confidence: 99%

“…The bioavailability of CBD depends on the route of administration [12]. CBD has low aqueous solubility (12.6 mg/L) and low bioavailability (4-20%) due to extensive first pass metabolism [13][14][15]. The poor oral bioavailability leads to low drug efficiency, hence a higher dose is required to reach the therapeutic concentration, which subsequently increases the risk of side effects and drug interactions [16].…”

Section: Introductionmentioning

confidence: 99%

Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration

et al. 2023

View full text Add to dashboard Cite

The use of cannabidiol (CBD) for treating brain disorders has gained increasing interest. While the mechanism of action of CBD in these conditions is still under investigation, CBD has been shown to affect numerous different drug targets in the brain that are involved in brain disorders. Here we review the preclinical and clinical evidence on the potential therapeutic use of CBD in treating various brain disorders. Moreover, we also examine various drug delivery approaches that have been applied to CBD. Due to the slow absorption and low bioavailability with the current oral CBD therapy, more efficient routes of administration to bypass hepatic metabolism, particularly pulmonary delivery, should be considered. Comparison of pharmacokinetic studies of different delivery routes highlight the advantages of intranasal and inhalation drug delivery over other routes of administration (oral, injection, sublingual, buccal, and transdermal) for treating brain disorders. These two routes of delivery, being non-invasive and able to achieve fast absorption and increase bioavailability, are attracting increasing interest for CBD applications, with more research and development expected in the near future.

show abstract

Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Phase 1 Clinical Study

Cited by 29 publications

References 24 publications

The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence

The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence

Oral inhalation of cannabidiol delivered from a metered dose inhaler to alleviate cytokine production induced by SARS-CoV-2 and pollutants

Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration

Contact Info

Product

Resources

About